• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Blueprint Medicines Corporation (Amendment)

    1/10/24 10:16:57 AM ET
    $BPMC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPMC alert in real time by email
    SC 13G/A 1 tv0016-blueprintmedicinescor.htm SCHEDULE 13G/A blueprintmedicinescorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  Blueprint Medicines Corp

    Title of Class of Securities:  Common Stock

    CUSIP Number:  09627Y109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  09627Y109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    110,994

    7.  SOLE DISPOSITIVE POWER

    5,940,691

    8.  SHARED DISPOSITIVE POWER

    174,279

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,114,970

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.06%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Blueprint Medicines Corp

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    45 Sidney Street
    Cambridge, MA 02139

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    09627Y109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  January 10, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $BPMC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BPMC

    DatePrice TargetRatingAnalyst
    3/20/2025$100.00Equal-Weight
    Morgan Stanley
    3/18/2025Outperform
    Wolfe Research
    3/17/2025$135.00Buy
    Jefferies
    3/7/2025$150.00Sector Outperform
    Scotiabank
    11/14/2024$126.00Overweight
    JP Morgan
    10/24/2024$88.00Neutral
    UBS
    5/14/2024$140.00Overweight
    Stephens
    5/6/2024$50.00 → $97.00Underperform → Market Perform
    Leerink Partners
    More analyst ratings

    $BPMC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

      -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -- --  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria – CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate updates. "Blueprint Medicines strives to be a top-tier s

      5/1/25 7:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 082088. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http:/

      4/25/25 8:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

      CAMBRIDGE, Mass., March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 12:45 p.m. ET. A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation. About Blueprint Medicine

      3/31/25 8:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Leadership Updates

    Live Leadership Updates

    See more
    • Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

      -- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAMBRIDGE, Mass., Nov. 22, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM). AYVAKIT was designed to potently and selectively inhibit D816V mutant KIT, the underlying cause of SM in about 95 percent of cases. The submission includes data from the registrationa

      11/22/22 4:36:00 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

      Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib treatment Study demonstrates need to identify C797X-driven resistance and tailor therapy options appropriately for patients with EGFR-mutant NSCLC Guardant Health Inc. (NASDAQ:GH), a leading precision oncology company, and Blueprint Medicines Corporation (NASDAQ:BPMC) announced today they are presenting new data demonstrating that the EGFR C797X mutation is the most common resistance mechanism to osimertinib therapy for patients with advanced non-small cell lung cancer (NSCLC). The results ar

      8/8/22 6:15:00 AM ET
      $BPMC
      $GH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Blueprint Medicines Publishes Inaugural Corporate Responsibility Report

      -- Report highlights efforts to deliver sustainable value to patients and communities, foster a diverse and empowered workforce, and operate with exceptional integrity -- CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today published its first Corporate Responsibility Report, highlighting its long-standing commitment to deliver sustainable value to patients with cancer and blood disorders, as well as the communities in which it operates. The report, which formalizes the company's efforts to track and report environmental, social and governance (ESG) standards and initiatives, includes summaries and performance metrics that demonstrate its purpos

      7/14/22 4:15:00 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Rossi Christina sold $231,386 worth of shares (2,274 units at $101.75), decreasing direct ownership by 3% to 66,992 units (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      5/7/25 4:32:25 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRINCIPAL ACCOUNTING OFFICER Hurley Ariel exercised 2,752 shares at a strike of $54.13 and sold $283,819 worth of shares (2,752 units at $103.13) (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      5/7/25 4:30:51 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Haviland Kate sold $216,461 worth of shares (2,498 units at $86.65), decreasing direct ownership by 1% to 165,929 units (SEC Form 4)

      4 - Blueprint Medicines Corp (0001597264) (Issuer)

      4/3/25 4:30:32 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Financials

    Live finance-specific insights

    See more
    • Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

      -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -- --  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria – CAMBRIDGE, Mass., May 1, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate updates. "Blueprint Medicines strives to be a top-tier s

      5/1/25 7:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 082088. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http:/

      4/25/25 8:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

      -- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approximately $680 million to $710 million in 2025, representing 45% percent year-over-year growth at the midpoint -- -- Peak systemic mastocytosis franchise revenue opportunity updated to $4 billion, with AYVAKIT expected to achieve $2 billion in revenue by 2030 -- -- AYVAKIT 3-year safety and efficacy results in ISM and BLU-808 healthy volunteer data among 14 total abstracts accepted for presentation at 2025 AAAAI / WAO Joint Congress -- CAMBRIDGE, Mass., Feb. 13, 2025 /PRNewswire/ -- Blueprint Medici

      2/13/25 7:00:00 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Blueprint Medicines with a new price target

      Morgan Stanley resumed coverage of Blueprint Medicines with a rating of Equal-Weight and set a new price target of $100.00

      3/20/25 7:59:08 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Blueprint Medicines

      Wolfe Research initiated coverage of Blueprint Medicines with a rating of Outperform

      3/18/25 7:49:08 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Blueprint Medicines with a new price target

      Jefferies initiated coverage of Blueprint Medicines with a rating of Buy and set a new price target of $135.00

      3/17/25 7:24:14 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Blueprint Medicines Corporation

      10-Q - Blueprint Medicines Corp (0001597264) (Filer)

      5/1/25 4:19:40 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blueprint Medicines Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Blueprint Medicines Corp (0001597264) (Filer)

      5/1/25 7:12:39 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Blueprint Medicines Corporation

      DEFA14A - Blueprint Medicines Corp (0001597264) (Filer)

      4/24/25 4:20:51 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPMC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Blueprint Medicines Corporation

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      11/14/24 1:22:36 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Blueprint Medicines Corporation (Amendment)

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      4/10/24 12:58:49 PM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Blueprint Medicines Corporation (Amendment)

      SC 13G/A - Blueprint Medicines Corp (0001597264) (Subject)

      2/14/24 10:03:02 AM ET
      $BPMC
      Biotechnology: Pharmaceutical Preparations
      Health Care